Clinical trial
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
NCT00420212 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00420212 |
|---|---|
| Title | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis |
| Official title | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis |
| Acronym | DEFINE |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | BG00012, Placebo |
| Enrollment | 1,234 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Jan 11, 2007 |
| Last update posted | Jan 26, 2015 |
| Countries | Australia, Austria, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czechia, France, Germany, Greece, Guatemala, India and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: